Clinical trials: Pancreatic Cancer Stage
Pancreatic Neoplasm
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve…
- Trial name
- NCT03310632
- Testing
- Antroquinonol
- Where
- 11 sites in United States, South Korea and 1 more
- Volunteers
- 55 people
- Sponsor
- Golden Biotechnology Corporation
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Advanced Solid Tumor, Gastric Cancer (GC)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
This is an open-label, dose escalation, dose expansion and extension cohort phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of SYSA1801
- Conditions
- Advanced Solid Tumor, Gastric Cancer (GC), Gastroesophageal Junction (GEJ) Cancer, Pancreatic Cancer
- Trial name
- NCT05009966
- Testing
- SYSA1801 for injection
- Where
- China
- Volunteers
- 272 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.
- Trial name
- HST (NCT03236883)
- Testing
- Gemcitabine, GPBSC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI…
- Trial name
- NCT04799431
- Testing
- Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00114179
- Testing
- capecitabine, radiation therapy, bevacizumab
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Pancreatic Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00004861
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Pancreatic Cancer
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, demcizumab (OMP-21M18), when given in combination with gemcitabine with or without (+/-) Abraxane®.
- Trial name
- NCT01189929
- Testing
- Demcizumab, Abraxane®, Gemcitabine
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 57 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced…
- Trial name
- NCT01146054
- Testing
- CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Stanford University
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Understanding New Cachexia Subtypes Through Observational Epidemiological Research
The UNCOVER study is a longitudinal observational cohort focused on patients at high risk for cancer cachexia. At Kaiser Permanente Northern California, up to 800 individuals with advanced or unresectable non-small cell lung…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- UNCOVER (NCT07776353)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic health record review
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Kaiser Permanente
Neoplasms
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
- Trial name
- NCT00475956
- Testing
- AZD2171, AZD0530
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Pancreatic Cancer Resectable
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
This is a randomized phase II trial that will examine the ability of Avelumab to improve the clinical activity of a pre-operative regimen of gemcitabine, nab-paclitaxel and hydroxychloroquine in subjects with potentially…
- Trial name
- 17-134 (NCT03344172)
- Testing
- Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab, Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Bahary, MD
Cholangiocarcinoma, Colorectal Cancer
TCR1188-ABC Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers.
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT07594067
- Testing
- TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Pancreatic Cancer
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00878657
- Testing
- gemcitabine hydrochloride, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinoma of Pancreas
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year.
- Trial name
- NCT01359007
- Testing
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Pancreatic Adenocarcinoma Advanced or Metastatic
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in…
- Trial name
- PANThEON (NCT06897644)
- Testing
- Oxaliplatin, Irinotecan (CPT-11), Leucovorin
- Where
- 28 sites in Italy
- Volunteers
- 340 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479…
- Trial name
- NCT01562899
- Testing
- MEK162, AMG 479
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.